Parenteral Drug Association Releases New Report on Manual Aseptic Processes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Parenteral Drug Association Releases New Report on Manual Aseptic Processes


The Parenteral Drug Association (PDA) released “Technical Report No. 62 (TR 62), Recommended Practices for Manual Aseptic Processes,” the association announced in a press release. The purpose of TR 62 is to outline methods and approaches for control and evaluation of aseptic processing operations for drug or medicinal products that use all or partially manual procedures.

TR 62 has value for hospital and formulation pharmacies where manual aseptic processing may occur. The guidance provided in this report may be applicable to operations including: vaccine preparation, cell culture, gene therapy, investigational new drug or medicinal product manufacturing, clinical and commercial manufacturing, and pharmacy formulation and dispensing. TR 62 is not intended to address the brief, relatively infrequent, human interventions into an otherwise automated filling process. Examples include reach-ins to remove a toppled vial from the filling line or to obtain a container for a fill-weight check, aseptic connections made during set-up, and corrective activities during line stoppages.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here